Review of novel therapeutic medicines targeting androgen signaling in castration-resistant prostate cancer

• 作者: Daisuke Obinata Hiroki Nagase Ken-ichi Takayama Kenya Yamaguchi Kyoko Fujiwara Noboru Fukuda Satoru Takahashi Satoshi Inoue Tomohiko Urano
• 来源期刊: 世界临床泌尿杂志
• 学科: 医学
• 关键词: ANDROGEN receptor PROSTATE cancer Pyrrole-imidazole POLYAMIDE
• 年，卷（期）: 2014,（3）
• 页码范围: 264-271
• 页数: 8页
• 分类号: R

摘要

Prostate cancer is the most common male malignant neoplasm.Androgens and the androgen receptor(AR)play a key role in the onset and progression of prostate cancer.The expression of the AR is still preserved in the majority of patients with castration-resistant prostate cancer(CRPC).CRPC is considered to be induced by the following mechanisms:(1)sustained AR activation by enhancing intracellular conversion of adrenal androgens to dehydrotestosterone via a de novo route;(2)AR hypersensitivity;(3)promiscuous activation of AR signaling;and(4)outlaw pathways.Recent advances in the treatment of CRPC include novel medicines targeting AR signaling pathways.In addition,functional molecular studies have shown that some of the ARregulated genes and AR coregulators are prognostic markers and potential therapeutic targets for prostate cancer,particularly in the castration-resistant state.Therefore,identification of the AR signaling pathways responsible for establishment of CRPC is critical for developing new strategies for the treatment of CRPC.